X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (527) 527
Book Review (101) 101
Publication (36) 36
Magazine Article (4) 4
Conference Proceeding (2) 2
Newspaper Article (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (422) 422
humans (393) 393
clarithromycin (344) 344
helicobacter pylori (212) 212
anti-bacterial agents - therapeutic use (207) 207
female (206) 206
male (203) 203
helicobacter infections - drug therapy (188) 188
adult (163) 163
middle aged (159) 159
clarithromycin - therapeutic use (150) 150
gastroenterology & hepatology (143) 143
infection (139) 139
treatment outcome (130) 130
drug therapy, combination (129) 129
aged (119) 119
pharmacology & pharmacy (118) 118
helicobacter pylori - drug effects (111) 111
antibiotics (95) 95
amoxicillin (90) 90
anti-bacterial agents - administration & dosage (90) 90
microbiology (83) 83
eradication (82) 82
helicobacter infections - microbiology (80) 80
amoxicillin - therapeutic use (73) 73
metronidazole (72) 72
clarithromycin - administration & dosage (70) 70
anti-bacterial agents - pharmacology (65) 65
management (64) 64
anti-bacterial agents - economics (62) 62
adolescent (60) 60
triple therapy (60) 60
infectious diseases (59) 59
therapy (59) 59
helicobacter pylori - isolation & purification (58) 58
anti-ulcer agents - therapeutic use (56) 56
helicobacter infections (56) 56
antibiotic-resistance (55) 55
azithromycin (55) 55
cost-benefit analysis (54) 54
medicine, general & internal (54) 54
resistance (54) 54
clarithromycin - economics (53) 53
erythromycin (53) 53
aged, 80 and over (52) 52
prevalence (52) 52
amoxicillin - administration & dosage (50) 50
efficacy (49) 49
helicobacter infections - diagnosis (49) 49
omeprazole (49) 49
abridged index medicus (48) 48
health aspects (48) 48
omeprazole - therapeutic use (48) 48
drug resistance, bacterial (47) 47
infections (47) 47
prospective studies (46) 46
antimicrobial resistance (45) 45
microbial sensitivity tests (45) 45
anti-bacterial agents - adverse effects (43) 43
clarithromycin - pharmacology (43) 43
drug therapy (42) 42
helicobacter infections - economics (41) 41
care and treatment (40) 40
clarithromycin resistance (40) 40
drug administration schedule (40) 40
proton pump inhibitors (38) 38
risk factors (38) 38
duodenal-ulcer (37) 37
research (37) 37
community-acquired infections - drug therapy (36) 36
diagnosis (35) 35
metaanalysis (35) 35
analysis (34) 34
community-acquired pneumonia (34) 34
double-blind method (34) 34
macrolides (34) 34
animals (33) 33
clarithromycin - adverse effects (33) 33
helicobacter infections - complications (33) 33
anti-ulcer agents - administration & dosage (32) 32
lansoprazole (32) 32
metronidazole - therapeutic use (32) 32
children (31) 31
drug resistance (31) 31
drug resistance in microorganisms (31) 31
levofloxacin (31) 31
pneumonia (31) 31
proton pump inhibitor (31) 31
antibacterial agents (30) 30
helicobacter infections - epidemiology (30) 30
helicobacter pylori - genetics (29) 29
medicine & public health (29) 29
anti-ulcer agents - economics (28) 28
breath tests (28) 28
epidemiology (28) 28
fluoroquinolones (28) 28
omeprazole - administration & dosage (28) 28
peptic ulcer - drug therapy (28) 28
retrospective studies (28) 28
time factors (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (509) 509
Russian (6) 6
Spanish (5) 5
French (4) 4
Korean (4) 4
Japanese (2) 2
Dutch (1) 1
German (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2003, Volume 1, Issue 4, pp. 273 - 278
Journal Article
BMJ, ISSN 0959-8138, 01/2006, Volume 332, Issue 7535, pp. 199 - 202
Journal Article
Gut, ISSN 0017-5749, 06/2019, Volume 68, Issue Suppl 2, p. A151
Introduction Helicobacter pylori (H. pylori) infection is the primary cause of peptic ulcer disease and is globally prevalent. Although eradication therapy is... 
Levofloxacin | Clarithromycin | Recurrent infection | Socio-economic aspects | Population studies | Infections | Drug resistance | Minority & ethnic groups | Patients | Ethnicity | Antibiotics | Biopsy | Antibiotic resistance | Amoxicillin | Metronidazole
Journal Article
Journal Article
Gut, ISSN 0017-5749, 11/2010, Volume 59, Issue 11, pp. 1465 - 1470
Journal Article
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 8, pp. 1135 - 1143
ABSTRACT Objective This study aimed to evaluate the length of stay (LOS), costs, and treatment consistency among patients hospitalized with community-acquired... 
Internal Medicine | cost | treatment outcomes | levofloxacin | length of stay | community-acquired pneumonia | hospital | moxifloxacin | Levofloxacin | Treatment outcomes | Community-acquired pneumonia | Hospital | Moxifloxacin | Cost | Length of stay | CLARITHROMYCIN | CONTROLLED-TRIAL | EFFICACY | SAFETY | ADULTS | ADHERENCE | CARE | AMERICA GUIDELINES | ORAL MOXIFLOXACIN | THERAPY | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | Fluoroquinolones | Multivariate Analysis | Confidence Intervals | Injections, Intravenous | Length of Stay - economics | Aza Compounds - therapeutic use | Humans | Ofloxacin - economics | Hospitalization - statistics & numerical data | Ofloxacin - therapeutic use | Diagnosis-Related Groups | Male | Statistics as Topic | Pneumonia, Bacterial - economics | Quinolines - administration & dosage | Quinolines - economics | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Statistics, Nonparametric | Ofloxacin - administration & dosage | Female | Retrospective Studies | Pulmonary Disease, Chronic Obstructive - economics | Length of Stay - statistics & numerical data | Databases, Factual | Anti-Bacterial Agents - economics | Aza Compounds - administration & dosage | Community-Acquired Infections - economics | Anti-Infective Agents - therapeutic use | Logistic Models | Treatment Outcome | Aza Compounds - economics | Propensity Score | Health Care Costs | Anti-Infective Agents - administration & dosage | Anti-Infective Agents - economics | Pneumonia, Bacterial - drug therapy | Aged | Quinolines - therapeutic use | Anti-Bacterial Agents - administration & dosage | Hospitalization - economics | Pulmonary Disease, Chronic Obstructive - drug therapy | Hospital patients | Pneumonia | Bacterial pneumonia | Comparative analysis | Medical care, Cost of | Index Medicus
Journal Article
Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, 09/2003, Volume 18, Issue 6, pp. 641 - 646
Journal Article
Digestive and Liver Disease, ISSN 1590-8658, 2004, Volume 36, Issue 5, pp. 322 - 326
Background and aim. One-week triple therapy for Helicobacter pylori revealed, during these last few years, a decrease in the eradication rate, so that the... 
Helicobacter pylori | Sequential therapy | Treatment duration | Triple therapy | DUODENAL-ULCER | TREATMENT REGIMENS | PLUS CLARITHROMYCIN | AMOXICILLIN | sequential therapy | treatment duration | triple therapy | PROTON PUMP INHIBITOR | VS. QUADRUPLE THERAPY | RANITIDINE BISMUTH CITRATE | ERADICATION THERAPY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCER | Multivariate Analysis | Anti-Ulcer Agents - economics | Prospective Studies | Humans | Middle Aged | Tinidazole - adverse effects | Antitrichomonal Agents - administration & dosage | Helicobacter Infections - complications | Male | Tinidazole - economics | Antitrichomonal Agents - adverse effects | Benzimidazoles - economics | Rabeprazole | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Peptic Ulcer - microbiology | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Antitrichomonal Agents - economics | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Clarithromycin - economics | Benzimidazoles - adverse effects | Drug Therapy, Combination | Anti-Bacterial Agents - economics | Dyspepsia - drug therapy | Drug Administration Schedule | Clarithromycin - adverse effects | Anti-Ulcer Agents - adverse effects | Treatment Outcome | Dyspepsia - microbiology | Anti-Ulcer Agents - administration & dosage | Smoking - epidemiology | Tinidazole - administration & dosage | 2-Pyridinylmethylsulfinylbenzimidazoles | Amoxicillin - adverse effects | Amoxicillin - economics | Patient Compliance | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Omeprazole - analogs & derivatives | Index Medicus
Journal Article
Journal Article
Chest, ISSN 0012-3692, 08/2003, Volume 124, Issue 2, pp. 526 - 535
To evaluate costs, clinical consequences, and cost-effectiveness from a German and French health-care system perspective of sequential IV/po moxifloxacin... 
community-acquired infections | economics, pharmaceutical | pneumonia, bacterial | costs and cost analysis